Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Cassava Sciences Inc (FLNA) vs Snowflake Inc (SNOW) Price & Performance

Cassava Sciences IncTrade
Snowflake IncTrade

Price performance (Past 24H)

Key statistics

Cassava Sciences Inc vs Snowflake Inc — how do they compare? Cassava Sciences Inc trades at $0.97 (market cap $47.75M), while Snowflake Inc trades at $330.06 (market cap $116.01B). The key difference: Snowflake Inc is far larger — about 2429.5× Cassava Sciences Inc's market cap, and Snowflake Inc is trading nearer its 52-week high, Cassava Sciences Inc nearer its low. Which is the better fit depends on your goals.

FLNASNOW
Market Cap
$47.75M$116.01B
Sector
HealthTechnology
52-Week High
$4.64$334.70
52-Week Low
$0.87$121.11
Enterprise Value
-$34.93M$115.82B

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Cassava Sciences Inc

FLNA trades at $0.9973, up 0.23% with a bearish technical signal despite recent earnings beats. The company shows negative profitability with ROE at -55.79% and ROA at -35.34%, though cash burn improved from -$33M to -$30M projected for 2026. Analyst consensus is strongly bullish with 8 buy ratings versus 4 hold ratings.

The outlook remains challenging due to persistent losses and negative cash flow, but analyst optimism and continued progress in TSC-related epilepsy therapies provide potential catalysts. Key risks include execution challenges in clinical development and the company's ability to secure additional funding.

Snowflake Inc

Snowflake (SNOW) trades at $334.7, up 1.27% on the day, reflecting strong momentum amid a bullish technical signal. The stock has consistently beaten earnings estimates in recent quarters, with Q1 2026 EPS of $0.39 exceeding expectations. Revenue growth remains robust, reaching $3.63 billion in 2025, though profitability challenges persist with a net income margin of -23.79%. Recent news highlights product innovations, including AI integrations and security enhancements, driving investor optimism.

Outlook is supported by Wall Street's bullish consensus, with 81% of analysts rating SNOW a buy and a price target of $302.18. However, high valuation multiples, intense competition, and ongoing losses present significant risks. The stock's proximity to its 52-week high suggests limited near-term upside without further positive catalysts.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Cassava Sciences Inc

Cassava Sciences Inc is a clinical-stage biotechnology company engaged in developing a scientific approach for the treatment and detection of Alzheimer's disease. Its therapeutic product candidate is called simufilam, and it is a novel treatment for Alzheimer's disease

Read more on FLNA

About Snowflake Inc

Founded in 2012, Snowflake is a data lake, warehousing, and sharing company that came public in 2020. To date, the company has over 3,000 customers including nearly 30% of the Fortune 500 as its customers. Snowflake's data lake stores unstructured and semistructured data that can then be used in analytics to create insights stored in its data warehouse. Snowflake's data sharing capability allows enterprises to easily buy and ingest data almost instantaneously compared with a traditionally months-long process. Overall, the company is known for the fact that all of its data solutions that can be hosted on various public clouds.

Read more on SNOW